These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 1371908)
1. Contrasting effects of alpha, beta, and gamma interferons on nonspecific suppressor function in multiple sclerosis. Noronha A; Toscas A; Jensen MA Ann Neurol; 1992 Jan; 31(1):103-6. PubMed ID: 1371908 [TBL] [Abstract][Full Text] [Related]
2. Interferon beta augments suppressor cell function in multiple sclerosis. Noronha A; Toscas A; Jensen MA Ann Neurol; 1990 Feb; 27(2):207-10. PubMed ID: 2138445 [TBL] [Abstract][Full Text] [Related]
3. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment]. Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835 [TBL] [Abstract][Full Text] [Related]
4. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209 [TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy. Becher B; Giacomini PS; Pelletier D; McCrea E; Prat A; Antel JP Ann Neurol; 1999 Feb; 45(2):247-50. PubMed ID: 9989628 [TBL] [Abstract][Full Text] [Related]
6. Natural suppressor (NS) activity from murine neonatal spleen is responsive to IFN-gamma. Maier T; Holda JH J Immunol; 1987 Jun; 138(12):4075-84. PubMed ID: 2953798 [TBL] [Abstract][Full Text] [Related]
7. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415 [TBL] [Abstract][Full Text] [Related]
8. Defective suppressor cell function mediated by T8+ cell lines from patients with progressive multiple sclerosis. Antel J; Bania M; Noronha A; Neely S J Immunol; 1986 Dec; 137(11):3436-9. PubMed ID: 2946761 [TBL] [Abstract][Full Text] [Related]
9. Accessory function of human fibroblasts in mitogen-stimulated interferon-gamma production by T lymphocytes. Inhibition by interleukin 1 and tumor necrosis factor. Le JM; Vilcek J J Immunol; 1987 Nov; 139(10):3330-7. PubMed ID: 3119705 [TBL] [Abstract][Full Text] [Related]
10. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients. Pentón-Rol G; Cervantes-Llanos M; Cabrera-Gómez JA; Alonso-Ramírez R; Valenzuela-Silva C; Rodríguez-Lara R; Montero-Casimiro E; Bello-Rivero I; López-Saura P Int Immunopharmacol; 2008 Jun; 8(6):881-6. PubMed ID: 18442793 [TBL] [Abstract][Full Text] [Related]
11. Activated suppressor cell function in severely disabled patients with multiple sclerosis. Antel JP; Freedman MS; Brodovsky S; Francis GS; Duquette P Ann Neurol; 1989 Feb; 25(2):204-7. PubMed ID: 2521994 [TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis: involvement of interferons in lesion pathogenesis. Traugott U; Lebon P Ann Neurol; 1988 Aug; 24(2):243-51. PubMed ID: 2460022 [TBL] [Abstract][Full Text] [Related]
13. Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function. Durelli L; Bongioanni MR; Cavallo R; Ferrero B; Ferri R; Verdun E; Bradac GB; Riva A; Geuna M; Bergamini L Mult Scler; 1995; 1 Suppl 1():S32-7. PubMed ID: 9345396 [TBL] [Abstract][Full Text] [Related]
15. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b. Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198 [TBL] [Abstract][Full Text] [Related]
16. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400 [TBL] [Abstract][Full Text] [Related]
17. Suppressor T cell activation by human leukocyte interferon. Schnaper HW; Aune TM; Pierce CW J Immunol; 1983 Nov; 131(5):2301-6. PubMed ID: 6226738 [TBL] [Abstract][Full Text] [Related]
18. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Link J; Söderström M; Olsson T; Höjeberg B; Ljungdahl A; Link H Ann Neurol; 1994 Sep; 36(3):379-86. PubMed ID: 8080246 [TBL] [Abstract][Full Text] [Related]
19. Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Revel M; Chebath J; Mangelus M; Harroch S; Moviglia GA Mult Scler; 1995; 1 Suppl 1():S5-11. PubMed ID: 9345390 [TBL] [Abstract][Full Text] [Related]
20. Regulation of the antigenic phenotype of human melanoma cells by recombinant interferons. Giacomini P; Gambari R; Barbieri R; Nisticò P; Tecce R; Pestka S; Gustafsson K; Natali PG; Fisher PB Anticancer Res; 1986; 6(5):877-84. PubMed ID: 2432832 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]